Provided by:

Thoracic Oncology Tumor Board 2022-2023

Thoracic Oncology Tumor Board 2022-2023 - 7/22/2022
July 22, 2022
8:00 AM - 9:00 AM
PCAM South 12-122

Target Audience
This program has been designed for Internal Medicine - Medical Oncology, Pathology - Clinical, Internal Medicine - Pulmonary Disease, Radiation Oncology, Thoracic And Cardiac Surgery, Pathology - Cytopathology, Pathology - Hematopathology, Pathology - Pathology-Molecular Genetic, Internal Medicine - Hospice And Palliative Medicine, Radiology , Surgery - Hospice And Palliative Medicine

Series Educational Objectives
After participating in this regularly scheduled series, participants should be able to:
1 Delineate institutional and national pathways/guidelines in the management of thoracic malignancy.
2 Facilitate multidisciplinary care and discussion to improve outcomes and quality of life.
3 Capitalize on the critical role of radiology and pathology in teh multidisciplanary management of thoracic cancer
4 Increase awareness clinical trials at the ACC and throughout the nation and to enhance enrollment in clinical trials.

Accreditation
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*
None

For more information, please contact
Megan Roy, Avyana Baker
(215) 360-0586, No phone on file
megan.roy@pennmedicine.upenn.edu, Avyana.Baker@Pennmedicine.upenn.edu

Check your transcript online at https://upenn.cloud-cme.com

Penn Medicine
Continuing Medical and Interprofessional Education

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Corey J Langer, MD	Co-Director	Advisor-Amgen|Grant or research support-Merck & Co|Advisor-Astra Zeneca Pharmaceuticals|Grant or research support-Janssen Pharmaceuticals (J&J)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Takeda Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novocure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc. - 01/28/2022
Megan Roy, MSN	Co-Director	Speakers Bureau-Astra Zeneca Pharmaceuticals - 02/07/2022
Aditi Singh, MD	Co-Director, Faculty	Nothing to disclose - 05/13/2022
Manuj Agarwal, MD	Other Planning Committee Member	Nothing to disclose - 11/12/2021
Charu Aggarwal, MD, MPH	Other Planning Committee Member	Advisor-Astra Zeneca Pharmaceuticals|Advisor-Genentech (Relationship has ended)|Advisor-Merck & Co|Advisor-Janssen Pharmaceuticals

		(J&J)|Advisor-Sanofi Genzyme|Advisor-Pfizer, Inc. - 06/14/2022
Keith Cengel, MD, PhD	Other Planning Committee Member	Nothing to disclose - 02/22/2022
Christine A Ciunci, MD	Other Planning Committee Member	Grant or research support-Celgene Corporation (Relationship has ended)|Honoraria-Merck & Co (Relationship has ended) - 05/17/2022
Roger Cohen, MD	Other Planning Committee Member	Consulting Fee-Astra Zeneca Pharmaceuticals|Consulting Fee-Heat|Grant or research support-Astra Zeneca Pharmaceuticals|Grant or research support-Innate|Grant or research support-Macrogenics|Grant or research support-Fstar|Grant or research support-Xencor|Consulting Fee-Cantargia|Grant or research support-Cantargia - 02/22/2022
Michael Costello, MD	Other Planning Committee Member	Nothing to disclose - 02/03/2022
Christopher D'avella, MD	Other Planning Committee Member	Nothing to disclose - 11/10/2021
Charuhas Deshpande, MD	Other Planning Committee Member	Nothing to disclose - 11/09/2021
David DiBardino, MD	Other Planning Committee Member	Consulting Fee-Olympus|Consulting Fee-Boston Scientific Corporation - 01/10/2022
steven Feigenberg, Md	Other Planning Committee Member	Honoraria-Astra Zeneca Pharmaceuticals (Relationship has ended)|Honoraria-Varian Medical Systems (Relationship has ended) - 11/10/2021
Narainder Gupta, FRCR	Other Planning Committee Member	Nothing to disclose - 02/10/2022
Andrew Haas	Other Planning Committee Member	Consulting Fee-Olympus|Paid consultant-Serpex Medical |Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novocure|Honoraria-Imedex|Consulting Fee-Mana Therapeutics (Relationship has ended)|Advisor-VisionAir - 11/12/2021
Doraid Jarrar, MD	Other Planning Committee Member	Nothing to disclose - 11/09/2021
Ana Kolansky, MD	Other Planning Committee Member	Nothing to disclose - 03/03/2022
John Kosteva, MD	Other Planning Committee Member	Nothing to disclose - 11/09/2021
John Kucharczuk, MD	Other Planning Committee Member	Speakers Bureau-Astra Zeneca Pharmaceuticals - 02/01/2022
william P levin, MD	Other Planning Committee Member	Nothing to disclose - 11/11/2021

Leslie Litzky, MD	Other Planning Committee Member	Nothing to disclose - 02/28/2022
Kevin Cong Ma, MD	Other Planning Committee Member	Nothing to disclose - 11/09/2021
melina marmarelis, MD	Other Planning Committee Member	Consulting Fee-Novocure (Relationship has ended)|Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended)|Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended)|Consulting Fee-Takeda Pharmaceuticals (Relationship has ended)|Consulting Fee-Bristol-Myers Squibb (Relationship has ended)|Grant or research support-Eli Lilly|Consulting Fee-Blueprint Pharmaceuticals (Relationship has ended)|Advisor-Ikena|Grant or research support-Merck & Co|Grant or research support-Astra Zeneca Pharmaceuticals|Stocks or stock options, excluding diversified mutual funds-Gilead Sciences, Inc|Stocks or stock options, excluding diversified mutual funds-Merck & Co|Stocks or stock options, excluding diversified mutual funds-Portola Pharmaceuticals|Stocks or stock options, excluding diversified mutual funds-Bluebird Biosciences|Stocks or stock options, excluding diversified mutual funds-Novartis (Advanced Health Media)|Stocks or stock options, excluding diversified mutual funds-Johnson & Johnson|Stocks or stock options, excluding diversified mutual funds-Pfizer, Inc. - 06/10/2022
Taine Pechet, MD	Other Planning Committee Member	Nothing to disclose - 11/09/2021
Kyle Robinson, MD	Other Planning Committee Member	Nothing to disclose - 02/28/2022
Lova Sun, MD	Other Planning Committee Member	Honoraria-Regeneron Pharmaceuticals, Inc. (Relationship has ended) - 11/09/2021

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected